TY  - BOOK
AU  - Ahmad Mahrous Dewidar 
AU  - Mohammad Ahmad Hassan , 
AU  - Mohammad Sayed Abdelkader , 
AU  - Wael Samir Makar , 
TI  - Carboplatin/gemcitabine as first line treatment of metastatic  triple negative breast cancer / 
PY  - 2015///
CY  - Cairo : 
PB  - Ahmad Mahrous Dewidar , 
KW  - Breast cancer
KW  - Metastatic
KW  - Triple negative
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of  Oncology (clinical); Issued also as CD
N2  - Background and objectives: Triple-negative breast cancer is  regarded as an aggressive disease for which effective targeted therapy is not yet  available. Results: Among the 34 included patients , 33 were considered valuable  for response as one patient refused to continue treatment after she received the  first week of treatment due to grade 3 vomiting, four patients (12.1%) achieved  complete response and 20 patients (60.6%) had a partial response giving an overall  response rate of 72.7% (95% CI, 60%-84%), one patients(3%) had stable disease >  6 months giving clinical benefit rate(CBR) of 75.7% (25/٣٣). The median  duration of response of 6.5 months. while 8 cases progressed in treatment (24.7%),  Median progression-free survival, was 6.18 months (95% CI 5.61{u2013}7·30 ) .Overall  survival was 12.7month (range2-24, SD: 5.1) .  Neutropenia G3 in 3 patients(9%) one of them developed febrile  neutropenia ,anemia grade three in 4\33 patients(12%), thrombocytopenia grade 3  in 5 patinets (15%).  Conclusions:. This study suggested that The combination was  efficacious and well tolerated   
ER  -